



# Development And Evaluation Of Mouth Dissolving Tablet Using Domperidone

<sup>1</sup>Sneha Patle, <sup>2</sup> Dr. Rajesh Mujariya, <sup>3</sup>Dr. Manjeet Singh, <sup>4</sup>Dr. Atul Bisen, <sup>5</sup>Dr.Surendra Pardhi

<sup>1,2,3,4,5</sup>Institute of Pharmaceutical Science and Research (IPSR), Balaghat, Madhy Pradesh, 481556

## Abstract:

In the present work, mouth dissolving tablets of domperidone were design with a view to enhance the patient compliance and provide a quick onset of action. Domperidone is antiemetic dopamine receptor antagonist and it has long half-life. The purpose of this study mouth dissolving tablets rapidly disintegrates in oral cavity and increase the dissolution so that the drug attains the therapeutic level in short time, so elicits better pharmacological effects. Mouth dissolving tablets prepared by direct compression and using super disintegrants like sodium starch glycolate, croscarmellose sodium and crospovidone in different concentration and evaluated for the pre-compression parameters such as bulk density, compressibility, angle of repose etc. The Mouth dissolving tabletformed was additionally found to be disintegrated within 1 min. The ratio of components in the Aqueous phase affected the thickness, drug content, tensile strength, percentage elongation, folding endurance, and release profile of Mouth dissolving tabletand the best results were obtained at DN2 formulation. Dissolution of prepared mouth dissolving tablet of Domperidone was performed using singhla apparatus in pH 6.8 phosphate buffer medium at 50 rpm with temperature being maintained at  $37 \pm 0.5^\circ\text{C}$ . The tabletprepared were evaluated for various parameters like thickness, weight variation, drug content uniformity, surface pH, folding endurance, disintegration time and in vitro drug release and were showed satisfactory results. The prepared batches of tablets were evaluated for hardness, weight variation, friability, drug content, disintegration time and in-vitro dissolution profile and found satisfactory. Among all, the formulation containing 5%w/w superdisintegrant crospovidone was considered to be best formulation, which release up to 98.15% in 15min.

**Keywords:** Mouth dissolving film, Domperidone, Superdisintegrants, Dissolution rate

## INTRODUCTION

Mouth dissolving tablets disintegrate and/or dissolve rapidly in the saliva without the need for water, releasing the drug. Some drugs are absorbed from the mouth, pharynx and esophagus as the saliva passes down into the stomach. In such cases, bioavailability of drug is significantly greater than those observed from conventional tablet dosage form<sup>1</sup>. Domperidone is selected as the model drug dopamine receptor

antagonist who comes under anti-emetic class<sup>6</sup>. Domperidone is optimized best suits for preparation of mouth dissolving tablets as it has longer half life and in case of vomiting it required quick release.<sup>2</sup> Among all the routes that have been investigated for the systemic delivery of pharmaceuticals via diverse pharmaceutical products of varied dose forms, oral drug delivery has been recognised for a decade as the most frequently used route administration. The oral route may have gained popularity due in part to its simplicity of administration as well as the conventional wisdom that the medicine is well absorbed when administered orally<sup>3</sup>, just like the meals that are consumed on a regular basis. For paediatric, geriatric, bedridden, queasy, or noncompliant patients, recent technological advances have made it possible to administer medications in ways that are equally effective as the oral route.<sup>4</sup> Fast dissolving tablets can be prepared by various conventional methods like direct compression, wet granulation, moulding, spray drying, freeze drying and sublimation<sup>5</sup>. Direct compression one of the techniques requires the incorporation of a superdisintegrants into the formulation the use or highly water soluble excipients to achieve fast tablet disintegration. Direct compression does not require the use of water or heat during the formulation procedure and is the ideal method for moisture and heat-labile medications.<sup>6</sup> The aim of purpose work was to formulate and characterization mouth dissolving tablets of domperidone for rapid dissolution of drug and absorption, which may produce the rapid onset of action in the treatment of emetic.<sup>7</sup>

## Material and Methods

Domperidone was obtained as a gift sample from Apex formulations, Chennai, India. Crospovidone and Lactose spray dried were gift sample from Signet Chemical Corporation, Mumbai. Croscarmellose sodium (Ac-Di-sol), Sodium starch glycolate (SSG) and Microcrystalline cellulose was gift samples from Sunrise Remedies, Ahmedabad, India. All chemicals and reagents used were of analytical grade.

## Preparation of Domperidone Solution

Sample solutions were prepared by dissolving the Domperidone in demineralised water (Table). All samples were prepared in 10 mM KCl solution with target final Domperidone concentration of 32.44 ppm. The analytical procedure was performed for all the samples and repeated four times. All the samples were sonicated for 3 min using Ultrasonic bath. These were filtered using 0.22 micron Whatmann filter G4 and investigated by the electronic tongue system and analyzed using UV spectroscopy at 240 nm for Domperidone formulations. The mV readings obtained from first run was discarded as per requirement of Insent System (This ensures the conditioning of sensors). All the data obtained for each sample were treated statistically by in-built software in the system.

**Table 1 Sample Preparation for Linearity Evaluation of Domperidone**

Domperidone concentrations (ppm)	Amount of Stock solution added ml
2.88	1.2ml
12	5.0ml
60	25ml
120	50ml
180	75ml

### Preparation of mouth dissolving tablets:

Domperidone mouth dissolving tablets were prepared by direct compression method. Different concentration of excipients was used to prepare different groups of mouth dissolving tablets. Compositions of various formulations are shown in Table 1. All the ingredients of the mouth dissolving tablets of domperidone were weighed and mixed in mortar with the help of pestle, then finally Aspartame,<sup>8</sup> 1mg Magnesium Sterate and 1mg was added material was slightly compressed on the 8mm flat-faced punch using a Rimek tablet press machine.<sup>9</sup> The total weight of the formulation was maintained 100mg.

**Formulation Table 2.**

INGREDIENT (mg)	FORMULATION CODE					
	F1	F2	F3	F4	F5	F6
Drug: complex Domperidone: Indion 204, (1:1)	20	20	20	20	20	20
Cross povidone	5	10	15	—	—	—
Croscarmellose sodium	—	—	—	5	10	15
MCC	60	55.45	61.95	60.00	55.00	50.05
Sodium Saccharin	10	10	10	10	10	10
Citric acid	0.5	0.05	0.05	0.05	0.05	0.05
Mg Stearate	3	3	3	3	3	3
Talc	2	2	2	2	2	2
Total weight (mg)	100	100	100	100	100	100

### PREFORMULATION STUDY

#### Organoleptic properties<sup>10</sup>

The received sample of Domperidone was examined for its appearance, colour and odour.

#### UV Spectroscopy study:<sup>11</sup>

Domperidone was produced as a stock solution in phosphate buffer at pH 6.8, and its absorption maxima ( $\lambda$  max) were determined by measuring the UV spectrum of a 10  $\mu$ g/ml solution


#### Calibration curve of Domperidone

With 10 ml of water, 10 mg of drug that had been precisely measured was dissolved. Domperidone solution of 20 g/ml was created from the principal stock solution using phosphate buffer solution. The range of this solution's scan was 200–400 nm.


## RESULTS AND DISCUSSION:

### Scanning of Domperidone by UV Spectrophotometry

The scanning of Domperidone was done as per the procedure described in methodology Section 4.3.



*Figure 1: UV Spectra of Domperidone in 0.1 N HCl at 241nm*




*Figure 2: UV Spectra of Domperidone in methanol at 241nm*

## Calibration Curve of Domperidone by UV Spectrophotometry in 0.1 N HCl

*Table . 3: Calibration Curve of Domperidone in 0.1 N HCl*


CONCENTRATION ( $\mu\text{g/ml}$ )	ABSORBANCE (mean $\pm$ SD)
0	$0.000 \pm 0.000$
2	$0.102 \pm 0.0032$
4	$0.162 \pm 0.0005$
6	$0.251 \pm 0.0040$
8	$0.327 \pm 0.0015$
10	$0.410 \pm 0.001$
12	$0.515 \pm 0.002$
14	$0.581 \pm 0.0015$
16	$0.642 \pm 0.0015$



*Figure . 3: Calibration curve of Domperidone in 0.1 N HCl*




## Characterisation of Drug and resins FTIR of Drug, Resins and Resinate



**Figure. 4: FTIR spectra of Drug, Resin and Resinate**

The interaction study between Domperidone and excipients in formulations were performed using FTIR spectrophotometer. The pellets were prepared on KBr press was introducing into FTIR spectra. The spectra were recorded over the wave number range of 4000 to 400  $\text{cm}^{-1}$ . The major IR peaks observed in Domperidone were 3325.64 (3300-3400) (N-H) stretching of 2°-amine, 1705.73 (1665-2000) C=C, a peak at 1279  $\text{cm}^{-1}$  representing C-N stretching of tertiary amine, 727.11 (600-800)  $\text{cm}^{-1}$  C-CL stretching in benzene ring. The absence of peaks at 1705  $\text{cm}^{-1}$  and 1279  $\text{cm}^{-1}$  in DRC confirms the complex formation of drug with resin. The peak at 3297.90  $\text{cm}^{-1}$  in DRC corresponding to -OH stretching is also absent, which signifies that during DRC formation there is an interaction of the amino group of drug with the carboxylic group of the resin.

## Differential Scanning Calorimetry (DSC)



**Figure 5: DSC thermogram of Drug, Resin and Resinate**

Samples were analyzed by DSC using shimadzu corporation, Japan. The samples were placed into a pieced aluminium sample container. The studies were performed under static air atmosphere in the temperature range of 50 °C- 250 °C at a heating rate of 10 °C per min. The peak temperatures were determined after calibration with a standard.

### Optimization of Drug and polymer complex 1:1 ratio

The process of preparing the drug–polymer was optimized with respect to drug-to-polymer ratio, sorption time, pH, and temperature. Drug loading was carried out by the batch method using polymers Cross povidone, a drug–polymer ratio of 1:1 achieved equilibrium within 3 hours, resulting in 96.83% drug–polymer complex formation. The optimized drug–polymer ratio was evaluated at different pH values (4.2, 5, 6, 7, and 8). Maximum complex formation (90.73%) was observed at pH 7, indicating that drug–polymer complex formation was minimal in more acidic environments. The effect of temperature was studied at 30, 40, 50, and 60 °C using the optimized drug–polymer ratio and pH. The highest percentage of complex formation (98.56%) was obtained at 40 °C, demonstrating that this temperature was optimal for drug loading compared to other studied conditions.

**Table.4: Amount of Complexed Drug at Different Mixing Times**

Drug: Polymer Ratio	Time(hrs.)	Free Drug (%)	Complexation Efficiency (%)
1:0.5	3	00.66	80.55
1:1	4	00.77	96.61



### Evaluation of Drug–Polymer Complex

**Table. 5: Evaluation Parameters of Drug–Polymer Complex**

Sr.No.	Parameter	Result
1	% Yield	83.00%
2	Angle of repose	29.88±0.16°
3	Bulk density	0.43±0.024
4	Tapped density	0.48±0.012
5	Carr's index	11.41±0.022
6	Hausner's Ratio	1.20±0.015

**Table. 6. FTIR study of Domperidone and polymers**



<b>Drug&amp; Excipient</b>	<b>Functional group</b>	<b>Peak (cm<sup>-1</sup>)</b>	<b>Mixture peak (cm<sup>-1</sup>)</b>	<b>Inference</b>
Domperidone	2°Amine	3345	3447	No Change
Croscarmellose sodium	Ether	1157	1153	No Change
	Methylene	1457	1458	
	Ether	1114	1108	
Crospovidone	Carbonyl group	1557	1556	No Change

**DSC analysis of Domperidone formulation****Domperidone Pure compound****Cross povidone**



## Croscarmollose

### Final formulations



**Figure 8: Thermogram of Drug and super disintegrants**

Results of the DSC study of pure drug showed sharp endothermic peak at 151.89 °C. Similar endothermic peaks were obtained in the formulations at 152.90 °C clearly indicated that there was no drug polymer interaction. Results of DSC thermo grams were shown in the Figure 8.

**Mouth dissolving tablet****Pre-formulation Studies****Table. 7: Melting point parameters**

Drug	Parameter		
	Melting Point	Loss on Drying	Partitions-coefficient
Domperidone	151°C	0.31% w/w	3.4

**Characterization of Mouth Dissolving Tablet****Determination of Weight Variation**

Weight of Mouth Dissolving Dosage Form was measured as per the methodology given in The weight of Mouth Dissolving Dosage Form was found to be in the range of 98.00 and 84 mg The results of weights are as shown in Table 7.

**Table. 7: Weight of Mouth Dissolving Dosage Form of Domperidone**


Weights in mg	F1	F2	F3	F4	F5	F6
	98.00	97	95	93	87	84

**In-vitro Disintegration Studies**

The in vitro disintegration time of the mouth dissolving dosage form was measured according to the methodology described. The disintegration time was found to be in the range of  $7.61 \pm 0.48$  seconds to  $16.33 \pm 0.58$  seconds. The results of the disintegration study are presented in Table. 8.

**Table. 8: Disintegration time of Mouth Dissolving Dosage Form of Domperidone**

DT in Sec	F1	F2	F3	F4	F5	F6
	7.61	10.66	12.22	10.93	12.95	15.16



**Figure 9: Disintegration time of M.D.T of Domperidone in optimized formula**


As the concentration of the polymer increases the disintegration time also increases which results in delayed release of drug.

### Measurement of Tensile Strength

Tensile strength of Mouth Dissolving Dosage Form was measured as per the methodology given in the tensile strength of Mouth Dissolving Dosage Form was found to be in the range of  $51.72 \pm 1.61 \text{ N/m}^2$  and  $75.66 \pm 0.67 \text{ N/m}^2$ . The results of tensile strength are as shown in Table 9.

**Table. 9: Tensile Strength of Mouth Dissolving Dosage Form of Domperidone**

Tensile strength N/m <sup>2</sup>	F1	F2	F3	F4	F5	F6
	51.72	56.51	59.93	58.61	65.58	69.70



**Figure 10: Tensile Strength of Domperidone Tablet**


As the concentration of the polymer increases the tensile strength increases. It determines the strength and durability of the tablet.

### Measurement of Percentage Elongation

Percentage Elongation of Mouth Dissolving Dosage Form was measured as per the methodology given in the Percentage Elongation of Mouth Dissolving Dosage Form was found to be in the range of  $21.69 \pm 0.64$  and  $34.45 \pm 0.88$ . The results of Percentage Elongation area shown in Table 10.

**Table. 10: Percentage Elongation of Mouth Dissolving Dosage Form of Domperidone**

Percentage Elongation	F1	F2	F3	F4	F5	F6
	34.45	32.52	29.66	30.08	27.84	24.86



**Figure 11: Percentage Elongation of Mouth Dissolving Dosage Form of Domperidone**


As the concentration of the polymer increases the percentage elongation decreases. Percentage elongation helps to determine the elasticity of the tablet.

## Determination of Drug Content

Drug content of Mouth Dissolving Dosage Form was measured as per the methodology given in the drug content of Mouth Dissolving Dosage Form was found to be in the range of  $97.73 \pm 0.63$  and  $99.56 \pm 0.57$  which was found within the acceptable limits as per IP. The results of drug content are as shown in Table 11.

**Table. 11: Drug Content of Mouth Dissolving Dosage Form of Domperidone**

	F1	F2	F3	F4	F5	F6
Drug content (%)	99.56	98.51	98.19	98.42	99.11	97.73



**Figure 12: % Drug Content in Mouth Dissolving Tablet of Domperidone**

As the concentration of the tablet increases the drug content decreases as the disintegration time is more. This parameter helps to identify the amount of drug present in the tablet.

## In-vitro Dissolution Studies

The in vitro dissolution study of the mouth dissolving dosage form was carried out according to the methodology. The percentage cumulative drug release of all optimized formulations is illustrated in Figure 13 increased, the disintegration time, resulting in a corresponding decrease in the rate of drug dissolution. The percentage cumulative drug release data are presented in Table 12.

Table. 12 : In Vitro Dissolution Study of Mouth Dissolving Dosage Form of Domperidone

	F1	F2	F3	F4	F5	F6
% cumulative drug release	99.68	99.02	98.45	99.24	98.87	96.14

Table. 13: In Vitro Drug Release at Different Time Intervals

Time (Sec)	F1	F2	F3	F4	F5	F6
0	0	0	0	0	0	0
2	80.94	77.67	75.81	78.32	76.54	72.79
4	83.13	80.45	79.65	82.04	80.07	76.86
6	85.52	82.95	81.06	84.14	81.98	79.62
8	88.24	86.09	85.69	86.68	85.92	81.66
10	91.05	90.23	89.72	90.75	89.91	87.93
15	94.91	94.02	73.13	94.45	93.67	91.25
20	97.82	97.06	96.32	97.43	96.76	94.8
25	98.75	98.14	97.54	98.37	97.93	95.67
30	99.68	99.02	98.45	99.24	98.87	96.14




Figure 13: % Cumulative drug release of formulations F1 to F6




The in-vitro drug release profiles of formulations F1–F6 are shown in Figure 13. All formulations exhibited a rapid initial drug release followed by a gradual increase in cumulative percentage release. Among them, formulation F1 showed the highest drug release (99.68%) at 30 minutes, whereas F6 showed comparatively slower release. The results indicate effective drug diffusion from the formulations with slight variation depending on composition.

### Surface pH

The surface pH of the mouth dissolving dosage form was measured according to the methodology. The surface pH of the mouth dissolving dosage form was found to be in the range of  $6.97 \pm 0.05$  to  $7.06 \pm 0.12$ , indicating a near-neutral pH. The results of the surface pH study are presented in Table 14.

**Table. 14: Surface pH of M. D. D. Form of Domperidone**

	F1	F2	F3	F4	F5	F6
Surface pH	6.97	7.00	7.06	6.93	7.03	6.90



**Figure 14: Drug Content in Mouth Dissolving Tablet of Domperidone (Optimized Formulation)**

### Stability study

Stability study was performed as per the procedure mentioned in methodology. Stability study results show that there was no significant change in disintegration time, drug content and in vitro drug release of the formulation. Table 15, 16 and 17.

**Table 15: Stability Study Data for Disintegration Time**

<b>Stability study at 20°C and 65%RH</b>	
<b>Test after time(days)</b>	<b>Disintegration time (Sec.)</b>
0	7.6
15	8.1
30	8.6

**Table 16: Stability Study Data for Drug content**

<b>Stability study at 30°C and 50% RH</b>	
<b>Test after time(days)</b>	<b>%drug content</b>
0	99.56
15	99.14
30	98.63

**Table 17: Stability Study Data for in-vitro studies**

<b>Stability study at 40°C and 75%RH</b>	
<b>Test after time(days)</b>	<b>%Cumulative drug release after 30 Sec.</b>
0	99.68
15	98.42
30	97.33

## DISCUSSION

In the present study particularly designed and developed mouth dissolving formulation Mouth dissolving tablet (MDT) immediate release of drug from the dosage form, to increase therapeutic efficacy and to improve patient compliance in case of allergy. Taste masked was done by batch method using Indion® 204; Complexes [1:1] were optimized by time, pH, and temperature and drug-resin proportion. These complexes were evaluated for angle of repose, bulk density, tapped density, Hausner's ratio, compressibility index and %yield. Taste masked done successfully by the resins indion-240. Optimum drug loading was found to be at drug-resin ratio 1:1, pH was 7 and at 30°C temperature within 3 hr. time. Optimized complex was further used for preparing MDT. The tablets were prepared by using synthetic super disintegrant (CP and CCS) at different concentrations. The prepared tablets were evaluated for weight variation, hardness, Friability,

disintegration time, wetting time, water absorption ratio, drug content and in vitro dissolution tests. The tablets were subjected for stability study at 40°C/65% RH. The results clearly show synthetic super disintegrant were easily release drug within less few seconds. It was concluded that mouth dissolving tablet of domperidone could be successfully prepared using synthetic polymers. The in-vitro drug release profiles of formulations F1–F6 are shown in Figure 13. All formulations exhibited a rapid initial drug release followed by a gradual increase in cumulative percentage release. Among them, formulation **F1** showed the highest drug release (**99.68%**) at 30 sec, whereas F6 showed comparatively slower release. The results indicate effective drug diffusion from the formulations with slight variation depending on composition.

## Reference

1. Ali M.S et.al 'Formulation and Evaluation of Fast Dissolving Oral Tablet of Diazepam' Jr of Pharmacovigilance, 2016 vol 4(3), p.no 1-5.
2. Alka Tomar et.al 'Formulation and Evaluation of Fast Dissolving Oral Tablet of Dicyclomine as potential route of buccal delivery' Int Jr Dr De & Res Jun 2012, vol 4(2), p.no 408-417.
3. Anjum Pathan et.al 'Formulation and Evaluation of Fast Dissolving Oral Tablet of Promethazine hydrochloride using different surfactant' Int Jr Ph & Bio Sci, 2016 vol 3(1), p.no 74-84.
4. Aulton ME, Wells TI, pharmaceuticals: the science of dosage from design. London, England: churchil; livingstone; 1998.
5. Bhyan B., Jangra S, Kaur M, Sing H. Orally Fast Dissolving Tablet : Innovations In Formulation and Technology. International Journal of Pharmaceutical Sciences Review and Research, 2011, 9: 50-56.
6. R. Tiwle, Effect of PH of AlCl<sub>3</sub> Solution on Drug Entrapment Efficiency of IPN Beads, International Journal of Chemistry and Pharmaceutical Sciences, IJCPS, 2014, Vol.2(6): 878-881.
7. British Pharmacopoeia. Electronic Edition, Crown Inc., London, 2007.
8. Buchi. N et.al 'Development and Evaluation of Fast Dissolving Tablet of Sumatriptan Succinate for better therapeutic efficacy' Jr App Ph Sci, Aug 2013 vol 3 (8), p.no 161-166.
9. Chen, M., Tirol, et.al "Tablet Forming Polymers In Fast Dissolve Oral Tablet " AAPS Annual meetings posters and papers, T3200, 2006.
10. Deepthi.A et.al 'Formulation and Evaluation of Fast Dissolving Thin Tablet .
11. Desai.P et.al 'Design and evaluation of fast dissolving tablet of Domperidone' Int Res Jr Ph 2012, 3(9), P.NO 134-135.
12. R. Tiwle, Effect of PH of AlCl<sub>3</sub> Solution on Drug Entrapment Efficiency of IPN Beads, International Journal of Chemistry and Pharmaceutical Sciences, IJCPS, 2014, Vol.2(6): 878-881
13. R. Tiwle, Saurabh Shrivastava, Suman Shrivastava., Validation of novel UV Spectrophotometric method for the determination of Ketoconazole in Pharmaceutical Formulation, J Pharm Adv Res, 2020; 3(2): 792-798.
14. Dr D. Nagendrakumar et.al 'Formulation and Evaluation of Fast Dissolving Oral Tablet of Metoprolol Succinate' Int Jr En & App Sci, 2015, vol 6 (4) p.no 28-36.
15. Dr. Arunakumari et.al 'Design and Evaluation of Losartan Potassium Fast Dissolving Tablet ' Int Jr Inn Ph Res, 2014, vol 5 (4) p.no 431-439.
16. PATEL M. Dasharath \* and Dharmendrasinh V. Dabhi. Development and Characterization of Oral Dissolving Tablet For Promethazine HCL 2014, 4728-4740.
17. R. Tiwle "An Exhaustive Review On Solubility Enhancement For Hydrophobic Compounds By Possible Applications Of Novel Techniques." Science Alert –Trends Research In Applied Science And Research. 7(8): 596-619; 2012.
18. Patel M.Dipal et.al 'Formulation and Evaluation of Fast Dissolving Tablet of Cetirizine & Dextromethorphan' Int Jr Ph Sci & Nanotech, 2016, vol 9 (3) p.no 3305-3311.